LD50=8500 mg/kg (rat, oral)
Common side effects include drowsiness or flushing (warmth, redness or tingly feeling).
Daily use of magnesium hydroxide can result in fluid and electrolyte disturbances.
Excessive use of the laxative effects of magnesium hydroxide may result in abdominal cramping, nausea and/or diarrhea.
In overdose, symptoms of gastrointestinal irritation and/or watery diarrhea may occur.
Magnesium hydroxide poisoning can result in hypermagnesemia which includes symptoms of: nausea, vomiting, flushing, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, muscle weakness, respiratory depression, cardiac arrhythmias, coma and cardiac arrest.
Not to be used in individuals with any form of kidney disease or renal failure, a magnesium restricted diet or with any sudden changes in bowel movement lasting over two weeks. Also not to be used in those individuals with abdominal pain, nausea, vomiting, symptoms of appendicitis or myocardial damage, heart block, fecal impaction, rectal fissures, intestinal obstruction or perforation or renal disease. Not to be used in women who are about to deliver as magnesium crosses the placenta and is excreted in small amounts in breast milk.
Using magnesium hydroxide with aluminum hydroxide can decrease the absorption rate of these drugs.
Magnesium hydroxide can react with digoxin, dicoumerol and cimetidine.
Use of ibuprofen with magnesium hydroxide can increase the absorption of the ibuprofen.
Use of magnesium hydroxide with penicallamine, bisphosphates, ketoconazole, quinolones or tetracycline can decrease the absorption of these drugs.
Enteric-coated tablets can be prematurely released when taken with magnesium hydroxide.
It is important to routinely monitor levels of serum magnesium and potassium in patients using magnesium hydroxide. Serum magnesium levels are necessary to determine how much magnesium is being absorbed and how much is being excreted by the kidneys. Excessive diarrhea can occur from use of magnesium hydroxide and thus it is important to also monitor serum potassium levels to ensure hypokalemia does not occur.
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form.
Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant.
It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium hydroxide. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Magnesium hydroxide. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Magnesium hydroxide. |
| Cisatracurium | Magnesium hydroxide may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium hydroxide. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium hydroxide. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium hydroxide. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium hydroxide. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium hydroxide. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium hydroxide. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium hydroxide. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium hydroxide. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium hydroxide. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium hydroxide. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium hydroxide. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium hydroxide. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium hydroxide. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium hydroxide. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium hydroxide. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Magnesium hydroxide. |
| Atazanavir | Magnesium hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Magnesium hydroxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium hydroxide. |
| Dabigatran etexilate | Magnesium hydroxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Magnesium hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Magnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Magnesium hydroxide can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Magnesium hydroxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Magnesium hydroxide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Magnesium hydroxide can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Magnesium hydroxide can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Magnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Magnesium hydroxide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Magnesium hydroxide can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcitriol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Calcitriol. |
| Calcifediol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Calcifediol. |
| Ergocalciferol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Ergocalciferol. |
| Cholecalciferol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Cholecalciferol. |
| Paricalcitol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Paricalcitol. |
| Dihydrotachysterol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Dihydrotachysterol. |
| Alfacalcidol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Alfacalcidol. |
| Seocalcitol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Seocalcitol. |
| Inecalcitol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Inecalcitol. |
| Becocalcidiol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Becocalcidiol. |
| Eldecalcitol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Eldecalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The serum concentration of Magnesium hydroxide can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2. |
| Elocalcitol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Elocalcitol. |
| Maxacalcitol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Maxacalcitol. |
| Doxercalciferol | The serum concentration of Magnesium hydroxide can be increased when it is combined with Doxercalciferol. |
| 1alpha-Hydroxyvitamin D5 | The serum concentration of Magnesium hydroxide can be increased when it is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The serum concentration of Magnesium hydroxide can be increased when it is combined with Previtamin D(3). |
| Deferiprone | Magnesium hydroxide can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | Magnesium hydroxide can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Magnesium hydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Magnesium hydroxide can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium hydroxide. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium hydroxide. |
| Captopril | Magnesium hydroxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium hydroxide. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium hydroxide. |
| Chloroquine | Magnesium hydroxide can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Elvitegravir | Magnesium hydroxide can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gabapentin enacarbil | The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium hydroxide. |
| Hyoscyamine | Magnesium hydroxide can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Magnesium hydroxide can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mecamylamine | Magnesium hydroxide may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Memantine | Magnesium hydroxide may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Penicillamine | Magnesium hydroxide can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Magnesium hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Quinine | Magnesium hydroxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotalol | The serum concentration of Sotalol can be decreased when it is combined with Magnesium hydroxide. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium hydroxide. |
| Deferasirox | Magnesium hydroxide can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Allopurinol | The therapeutic efficacy of Allopurinol can be decreased when used in combination with Magnesium hydroxide. |
| Fexofenadine | Magnesium hydroxide can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Magnesium hydroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Magnesium hydroxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Misoprostol | The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Misoprostol. |
| Mesalazine | Magnesium hydroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Magnesium hydroxide. |
| Ketoconazole | Magnesium hydroxide can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trospium | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Trospium. |
| Oxyphenonium | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxyphenonium. |
| Ziprasidone | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ziprasidone. |
| Ipratropium | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ipratropium. |
| Olanzapine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Olanzapine. |
| Metixene | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Metixene. |
| Terfenadine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Terfenadine. |
| Buclizine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Buclizine. |
| Doxylamine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Doxylamine. |
| Trihexyphenidyl | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Trihexyphenidyl. |
| Oxyphencyclimine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxyphencyclimine. |
| Procyclidine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Procyclidine. |
| Profenamine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Profenamine. |
| Cyproheptadine | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Cyproheptadine. |
| Methscopolamine bromide | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Methscopolamine bromide. |
| Darifenacin | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Darifenacin. |
| Tridihexethyl | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tridihexethyl. |
| Anisotropine methylbromide | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Anisotropine methylbromide. |
| Nortriptyline | The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Nortriptyline. |